FLDM Fluidigm

Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm’s fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.

The presentation will be webcast live and available on the Investor Relations page of the Company’s website at . A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at .

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: . Patent and License Information: .

Trademarks: . Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact: 

David Holmes

Gilmartin Group LLC

(332) 330-1031

  



EN
26/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fluidigm

 PRESS RELEASE

Standard BioTools proteomics profiling reveals unique biomarkers and i...

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced a , by researchers at Pfizer Research and Development, that detailed their use of the high-plex SomaScan® Assay, leveraging an industry-leading 7,000-protein biomarker...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 31, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Standard BioTools to Present at the Morgan Stanley 22nd Annual Global ...

Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm’s fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET. The presentation will be webcast live and available on the Investor Rela...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch